Dimethylarginine: Biomarkers in progression of kidney disease
Decreased nitric oxide (NO) production and/or impaired NO bioavailability may occur in patients with the chronic kidney disease (CKD), and could contribute to elevation of blood pressure, cardiovascular disease (CVD) and progression of renal injury in these patients. Free guanidinomethylated arginin...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Medical Biochemists of Serbia, Belgrade
2012-01-01
|
| Series: | Journal of Medical Biochemistry |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2012/1452-82581204301C.pdf |
| _version_ | 1819076281625477120 |
|---|---|
| author | Cvetković Tatjana Pavlović Radmila Đorđević Vidosava Stojanović Ivana Veličković-Radovanović Radmila Ignjatović Aleksandra Stefanović Nikola Živanović Slavoljub Đorđević Vidojko |
| author_facet | Cvetković Tatjana Pavlović Radmila Đorđević Vidosava Stojanović Ivana Veličković-Radovanović Radmila Ignjatović Aleksandra Stefanović Nikola Živanović Slavoljub Đorđević Vidojko |
| author_sort | Cvetković Tatjana |
| collection | DOAJ |
| description | Decreased nitric oxide (NO) production and/or impaired NO bioavailability may occur in patients with the chronic kidney disease (CKD), and could contribute to elevation of blood pressure, cardiovascular disease (CVD) and progression of renal injury in these patients. Free guanidinomethylated arginine residues occur endogenously as a result of proteolysis of post-translational methylated tissue proteins. The asymmetric dimethyl arginine (ADMA) is a competitive inhibitor of the nitric oxide synthase (NOS) enzymes. The kidney has a predominant role in ADMA elimination by combining two mechanisms; urinary excretion and metabolization of ADMA The degradation of ADMA is accomplished intracellularly by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). ADMA is not only a uremic toxin, but also a strong marker of the endothelial dysfunction and atherosclerosis and a stronger independent predictor of all-cause mortality and cardiovascular outcome in patients with the chronic renal failure. There are at least four mechanisms that may explain the accumulation of ADMA in CKD: increased methylation of proteins, increased protein turnover, decreased metabolism by DDAH and impaired renal excretion. A strong positive correlation between symmetric dimethyl arginine (SDMA) and creatinine suggests that SDMA might be of value as a marker of the renal function. Reduced NO elaboration secondary to accumulation of ADMA and elevated inflammation may be important pathogenic factors for endothelial dysfunction in patients with the renal disease. Elevation of ADMA may be a missing link between CVD and CKD. |
| first_indexed | 2024-12-21T18:38:49Z |
| format | Article |
| id | doaj.art-7f98e10436bb4bf3bb860e12dd0b066a |
| institution | Directory Open Access Journal |
| issn | 1452-8258 1452-8266 |
| language | English |
| last_indexed | 2024-12-21T18:38:49Z |
| publishDate | 2012-01-01 |
| publisher | Society of Medical Biochemists of Serbia, Belgrade |
| record_format | Article |
| series | Journal of Medical Biochemistry |
| spelling | doaj.art-7f98e10436bb4bf3bb860e12dd0b066a2022-12-21T18:54:03ZengSociety of Medical Biochemists of Serbia, BelgradeJournal of Medical Biochemistry1452-82581452-82662012-01-013143013081452-82581204301CDimethylarginine: Biomarkers in progression of kidney diseaseCvetković Tatjana0Pavlović Radmila1Đorđević Vidosava2Stojanović Ivana3Veličković-Radovanović Radmila4https://orcid.org/0000-0001-9055-3378Ignjatović Aleksandra5https://orcid.org/0000-0002-2689-8088Stefanović Nikola6Živanović Slavoljub7Đorđević Vidojko8Institute of Biochemistry, Medical Faculty, Niš + Clinic of Nephrology and Haemodialysis, Clinical Center, NišInstitute of Chemistry, Medical Faculty, NišInstitute of Biochemistry, Medical Faculty, NišInstitute of Biochemistry, Medical Faculty, NišClinic of Nephrology and Haemodialysis, Clinical Center, NišDepartment of Medical Statistics, Medical Faculty, NišResearch Center for Biomedicine, Medical Faculty, NišDepartment of Medical Statistics, Medical Faculty, NišClinic of Nephrology and Haemodialysis, Clinical Center, NišDecreased nitric oxide (NO) production and/or impaired NO bioavailability may occur in patients with the chronic kidney disease (CKD), and could contribute to elevation of blood pressure, cardiovascular disease (CVD) and progression of renal injury in these patients. Free guanidinomethylated arginine residues occur endogenously as a result of proteolysis of post-translational methylated tissue proteins. The asymmetric dimethyl arginine (ADMA) is a competitive inhibitor of the nitric oxide synthase (NOS) enzymes. The kidney has a predominant role in ADMA elimination by combining two mechanisms; urinary excretion and metabolization of ADMA The degradation of ADMA is accomplished intracellularly by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). ADMA is not only a uremic toxin, but also a strong marker of the endothelial dysfunction and atherosclerosis and a stronger independent predictor of all-cause mortality and cardiovascular outcome in patients with the chronic renal failure. There are at least four mechanisms that may explain the accumulation of ADMA in CKD: increased methylation of proteins, increased protein turnover, decreased metabolism by DDAH and impaired renal excretion. A strong positive correlation between symmetric dimethyl arginine (SDMA) and creatinine suggests that SDMA might be of value as a marker of the renal function. Reduced NO elaboration secondary to accumulation of ADMA and elevated inflammation may be important pathogenic factors for endothelial dysfunction in patients with the renal disease. Elevation of ADMA may be a missing link between CVD and CKD.https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2012/1452-82581204301C.pdfnitric oxide (no)asymmetric dimethyl arginine(adma)kidney diseaseendothelial dysfunction |
| spellingShingle | Cvetković Tatjana Pavlović Radmila Đorđević Vidosava Stojanović Ivana Veličković-Radovanović Radmila Ignjatović Aleksandra Stefanović Nikola Živanović Slavoljub Đorđević Vidojko Dimethylarginine: Biomarkers in progression of kidney disease Journal of Medical Biochemistry nitric oxide (no) asymmetric dimethyl arginine(adma) kidney disease endothelial dysfunction |
| title | Dimethylarginine: Biomarkers in progression of kidney disease |
| title_full | Dimethylarginine: Biomarkers in progression of kidney disease |
| title_fullStr | Dimethylarginine: Biomarkers in progression of kidney disease |
| title_full_unstemmed | Dimethylarginine: Biomarkers in progression of kidney disease |
| title_short | Dimethylarginine: Biomarkers in progression of kidney disease |
| title_sort | dimethylarginine biomarkers in progression of kidney disease |
| topic | nitric oxide (no) asymmetric dimethyl arginine(adma) kidney disease endothelial dysfunction |
| url | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2012/1452-82581204301C.pdf |
| work_keys_str_mv | AT cvetkovictatjana dimethylargininebiomarkersinprogressionofkidneydisease AT pavlovicradmila dimethylargininebiomarkersinprogressionofkidneydisease AT đorđevicvidosava dimethylargininebiomarkersinprogressionofkidneydisease AT stojanovicivana dimethylargininebiomarkersinprogressionofkidneydisease AT velickovicradovanovicradmila dimethylargininebiomarkersinprogressionofkidneydisease AT ignjatovicaleksandra dimethylargininebiomarkersinprogressionofkidneydisease AT stefanovicnikola dimethylargininebiomarkersinprogressionofkidneydisease AT zivanovicslavoljub dimethylargininebiomarkersinprogressionofkidneydisease AT đorđevicvidojko dimethylargininebiomarkersinprogressionofkidneydisease |